Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition

On November 3, 2022 Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases reported that it will have a poster presentation for ALPN-303’s phase 1 study (RUBY-1) at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition, December 10-13, 2022 (Press release, Alpine Immune Sciences, NOV 3, 2022, View Source [SID1234622900]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date/Time: December 12, 2022, at 6:00pm – 8:00pm EST
Poster Title: A Randomized, Placebo-Controlled, Phase 1 Study of Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias
Poster Number: 3763
Session Name: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III
Location: Ernest N. Morial Convention Center, Hall D

About ALPN-303 and the RUBY-1 Phase 1 Study

ALPN-303 is a dual antagonist of the BAFF (B cell activating factor) and APRIL (proliferation inducing ligand) cytokines, which play key roles in the survival and activation of B cells. Based upon an engineered TACI (transmembrane activator and CAML interactor) domain, ALPN-303 exhibits greater potency in preclinical studies versus comparators based on wild-type TACI, as well as other inhibitors of BAFF and/or APRIL alone. ALPN-303 is in development for multiple B cell and/or autoantibody-related diseases, such as systemic lupus erythematosus, glomerulonephritides, and autoimmune cytopenias.

RUBY-1 (NCT05034484) is a phase 1, randomized, placebo-controlled study in healthy adult volunteers designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of intravenously and subcutaneously administered ALPN-303. Initial data show ALPN-303 to be well tolerated up to 960 mg with dose-dependent pharmacokinetics and reductions in circulating immunoglobulins and antibody-secreting cells, supporting the use of a once every four-week dose regimen for subsequent studies.